Noveris Health Sciences is trading at $0.10, down -9.52%, with no new company-specific announcement or confirmed catalyst identified for September 9, 2026.
- Recent disclosures included a C$500,000 convertible-debenture financing and second-quarter results, but available coverage does not directly link either item to today’s decline.
- Broader markets are modestly lower, though the move is insufficient to establish a clear macro explanation.